Table 7.

Univariate and multivariate regression analysis of PFS (immunotherapy group).

Factor	Univariate			Multivariate
	HR1	95%CI1	P-value	HR1	95%CI1	P-value
Line of Therapy	0.683	0.860, 5.397	0.717	–	–	–
Types of ICIs	0.265	0.350, 2.030	0.200	0.477	0.570, 3.964	0.493
Subsequent Treatment	0.582	0.330, 1.024	0.061	0.624	0.343, 1.137	0.123

PFS, progression free survival; OS, overall survival. Line of Therapy: Including first-line therapy, second-line therapy, third-line therapy, and fourth-line therapy; Types of ICIs (Immune Checkpoint Inhibitors): Camrelizumab, Serplulimab, Toripalimab, Sintilimab, Pembrolizumab, Tislelizumab, Adebrelimab, and Envafolimab. Of these, Adebrelimab and Envafolimab are PD-L1 inhibitors, while the remaining agents are classified as PD-1 inhibitors; Subsequent Treatment: Continued antitumor therapy (excluding immunotherapy), symptomatic treatment, death during immunotherapy, stable disease status post-immunotherapy (with no further treatment administered). In the multivariate analysis, bold values indicate P < 0.2, while in the univariate analysis table, bold values indicate P < 0.05.